{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Oza B"],"funding":["AstraZeneca plc","Cancer Research UK","Medical Research Council"],"pagination":["106482"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8520913"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["108"],"pubmed_abstract":["<h4>Background</h4>20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting.<h4>Methods/design</h4>RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional research"],"journal":["Contemporary clinical trials"],"pubmed_title":["RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse."],"pmcid":["PMC8520913"],"funding_grant_id":["MC_UU_00004/09","28690","MC_UU_00004/01"],"pubmed_authors":["Shakeshaft C","Bex A","McWhirter A","Oza B","Parmar MKB","Harrison D","Fielding A","Scovell S","Meade A","Nathan P","Mulhere S","Davis ID","Rini B","Stewart GD","Kaplan R","Smith B","Albiges L","Ritchie A","Choueiri TK","Larkin J","Eisen T","Frangou E","Powles T","Stockler MR","Thorogood N","Choodari-Oskooei B","Bryant H"],"additional_accession":[]},"is_claimable":false,"name":"RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.","description":"<h4>Background</h4>20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, radiotherapy, hormones and oral tyrosine-kinase inhibitors (TKIs), with limited success. The predominant global standard-of-care after nephrectomy remains active monitoring. Immune checkpoint inhibitors (ICIs) are effective in the treatment of metastatic RCC; RAMPART will investigate these agents in the adjuvant setting.<h4>Methods/design</h4>RAMPART is an international, UK-led trial investigating the addition of ICIs after nephrectomy in patients with resected locally advanced RCC. RAMPART is a multi-arm multi-stage (MAMS) platform trial, upon which additional research","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-04-05T12:56:21.227Z","creation":"2025-04-05T12:56:21.227Z"},"accession":"S-EPMC8520913","cross_references":{"pubmed":["34538402"],"doi":["10.1016/j.cct.2021.106482"]}}